Summary: In adults with moderate-to-severe alcohol use disorder and comorbid obesity, once-weekly semaglutide 2.4 mg for 26 weeks reduced heavy drinking days more than placebo (treatment difference -13.7 percentage points; p=0.0015) alongside weight loss, at the cost of transient gastrointestinal side effects.
PICO Summary
| Element | Detail |
|---|---|
| Population | 108 treatment-seeking adults with moderate-to-severe alcohol use disorder and comorbid obesity (single-centre). |
| Intervention | Once-weekly subcutaneous semaglutide 2.4 mg for 26 weeks, plus standard cognitive behavioural therapy. |
| Comparison | Once-weekly placebo (saline) plus the same cognitive behavioural therapy. |
| Outcome | Greater reduction in heavy drinking days (-41.1 vs -26.4 percentage points; treatment difference -13.7; 95% CI -22.0 to -5.4; p=0.0015), with benefit on secondary alcohol and somatic outcomes. Transient, mostly mild-to-moderate gastrointestinal adverse events. |
Semaglutide for alcohol use disorder
RCT · AUD + obesity · 26 weeks
Once-weekly semaglutide 2.4 mg cut heavy drinking days by 13.7 percentage points more than placebo over 26 weeks in adults with alcohol use disorder and obesity. A single-centre phase 2 signal that needs phase 3 confirmation.
Expert Commentary
The idea that a drug I already prescribe for weight might also curb drinking is genuinely exciting, because alcohol use disorder is common, undertreated, and served by only a handful of modestly effective medicines. This is one of the better randomised tests of that hypothesis, and the signal is real: a 13.7 percentage-point reduction in heavy drinking days over placebo, on top of cognitive behavioural therapy, is a meaningful effect with a plausible mechanism in central reward circuitry. I am enthusiastic but deliberately restrained, because this is a single-centre phase 2 trial of 108 people over 26 weeks, the participants all had obesity so I cannot extrapolate to normal-weight patients, and the prominent gastrointestinal effects can unblind a self-reported drinking outcome. Semaglutide is not approved for this, and these data do not license off-label prescribing for alcohol alone. Can I use this with my patients? Only in the specific case of someone who already qualifies for semaglutide through obesity or diabetes and who also has alcohol use disorder, where a dual benefit is a welcome bonus alongside naltrexone, acamprosate, and psychosocial care. I want the larger phase 3 trials before calling this an addiction treatment.
References
Klausen MK, Justesen SK, Pedersen JN, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet. 2026;407(10540):1687–1698. doi:10.1016/S0140-6736(26)00305-3